Denali Therapeutics Inc. (DNLI)
$
18.16
-1.58 (-8.70%)
Key metrics
Financial statements
Free cash flow per share
-2.4057
Market cap
2.9 Billion
Price to sales ratio
0
Debt to equity
0.0417
Current ratio
9.1576
Income quality
0.8050
Average inventory
0
ROE
-0.5013
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Denali Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of therapeutic candidates for neurodegenerative diseases based in the United States. The company recorded a notable revenue of $0.00 showcasing its steady growth in a challenging industry. The earnings per share (EPS) is reported at -$2.97 indicating the company's profitability on a per-share basis, despite facing operational challenges. Its operating expenses amount to $544,159,000.00 encompassing various operational costs incurred during development. The EBITDA ratio is 0.00 highlighting the company's operational efficiency in its ongoing and future projects. However, the company reported a net loss of -$512,540,000.00 indicating challenges in its operations as it continues to invest in innovative therapies. Denali offers a range of therapeutic candidates, such as the LRRK2 inhibitor product candidate BIIB122/DNL151, which is currently in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. Additionally, the company is progressing with DNL310 in Phase I/II trials for Hunter syndrome, and DNL343 in phase 1 trials for amyotrophic lateral sclerosis (ALS). Completing a phase I clinical trial, AR443820/DNL788 targets ALS, multiple sclerosis (MS), and Alzheimer's disease, while SAR443122/DNL758 is in phase II trials for cutaneous lupus erythematosus. The company collaborates with notable partners including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, and the Michael J. Fox Foundation, among others, to enhance its research and development efforts. In the financial landscape, the stock is affordable at $12.75 suitable for budget-conscious investors looking to enter the biopharmaceutical market. It has an average trading volume of 1,615,496.00 indicating moderate liquidity, which may appeal to a broad range of investors. With a mid-range market capitalization of $2,880,012,560.00 the company is a steady performer that plays an essential role in the biopharmaceutical industry, contributing significantly to the overall market landscape. Denali Therapeutics belongs to the Healthcare sector, driving innovation and growth, underscoring its commitment to addressing unmet medical needs in neurodegenerative diseases and beyond.
Is Denali Therapeutics Inc. (DNLI) a good investment?
Investing in Denali Therapeutics Inc. (DNLI) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Denali Therapeutics Inc. (DNLI)'s stock forecast?
Analysts predict Denali Therapeutics Inc. stock to fluctuate between $10.57 (low) and $23.77 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Denali Therapeutics Inc.'s market capitalization?
As of 2026-03-27, Denali Therapeutics Inc.'s market cap is $2,880,012,560, based on 158,591,000 outstanding shares.
How does Denali Therapeutics Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Denali Therapeutics Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Denali Therapeutics Inc. (DNLI) stock?
To buy Denali Therapeutics Inc. (DNLI) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DNLI. Place an order (Market, Limit, etc.).
What is the best time to invest in Denali Therapeutics Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Denali Therapeutics Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.97 | Growth: 15.56%.
Where can I find Denali Therapeutics Inc.'s investor relations reports?
Visit https://www.denalitherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Denali Therapeutics Inc.?
You can explore historical data from here
What is the all-time high and low for Denali Therapeutics Inc. stock?
All-time high: $56.80 (2021-09-02) | All-time low: $10.57 (2025-04-07).
What are the key trends affecting Denali Therapeutics Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
DNLI surges after FDA approves Avlayah, its first commercial drug and a breakthrough Hunter syndrome therapy targeting the brain.
globenewswire.com
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for AVLAYAH™ (tividenofusp alfa-eknm), the first FDA-approved biologic specifically designed to cross the blood-brain barrier and reach the whole body, including the brain. AVLAYAH is an enzyme replacement therapy indicated for the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial.
seekingalpha.com
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript
zacks.com
DNLI stock jumps as investors eye an April 5, 2026, FDA decision on tividenofusp alfa for Hunter syndrome, a key catalyst for growth.
cnbc.com
The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna's flu shot before reversing course.
seekingalpha.com
Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript
globenewswire.com
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced data from programs in Hunter syndrome (mucopolysaccharidosis type II, MPS II), Sanfilippo syndrome type A (MPS IIIA) and Pompe disease that highlight the potential of its Enzyme TransportVehicle™ (ETV) to enable the delivery of enzyme replacement therapies (ERT) to the whole body, including the brain. Data were presented this week at the 22nd Annual WORLDSymposium™ in San Diego, California.
247wallst.com
The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the market, as growth in other sectors of the economy have led to valuations that now look more elevated than the biotech sector (in many cases).
seekingalpha.com
Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
zacks.com
DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.
See all news
